Meralgia Paresthetica, locating the lateral femoral cutaneous nerve (LFCN) with elektro-stimulation followed by a therapeutic injection of methylprednisolone/lidocaïne (M/L), a double-blind randomized placebo-controlled clinical trial
Completed
- Conditions
- Sensory entrapment neuropathy10034606
- Registration Number
- NL-OMON44713
- Lead Sponsor
- HagaZiekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Adult patients with newly diagnosed idiopathic meralgia paresthetica will be recruited. Age: 18 years and older. Duration 4 weeks or more.
Diagnostic criteria: Meralgia paresthetica characterized by pain, numbness and tingling in the anterolateral aspect of the thigh in the area of the LFCN
Exclusion Criteria
1. Coexisting disorders or conditions that may mimic MP such as lumbar radiculopathy, severe polyneuropathy.
2. Known allergic reaction to methylprednisolone/lidocaine.
3. Pregnancy
4. No localization possible through electrostimulation
5. Systemic viral or fungal infections
6. Known allergy to steroids
7. No injection with steroids can be given in a vicinity of a preexistent infectious area
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Primary endpoint will be reduction of the pain score on a visual analogue scale<br /><br>(VAS). </p><br>
- Secondary Outcome Measures
Name Time Method <p>Secondary endpoints are:<br /><br>- Pain reduction after injection measured on a different scale (pain worsening,<br /><br>no improvement of pain, slight to moderate improvement of pain, complete<br /><br>remission of pain.)<br /><br>- Duration of pain reduction<br /><br>- Reduction of oral analgetics ( descriptive)</p><br>